-
3D Tumor Spheroid Assay for Glioblastoma Stemness Detection
2026-04-30
This study introduces a streamlined 3D tumor spheroid assay to efficiently assess stemness in glioblastoma cell lines. The method offers a reproducible platform for functional evaluation of glioma stem-like properties, reducing assay time and resource needs, and enabling high-throughput drug screening and mechanistic studies.
-
In Situ PD-L1 Editing Enhances Tumor Immunotherapy Efficacy
2026-04-30
This study introduces a peptide-based self-assembling nanoparticle (TPM1) that aggregates and captures PD-L1 proteins on tumor cell membranes, facilitating robust PD-1/PD-L1 pathway blockade. The innovation demonstrates prolonged tumor retention and improved immunotherapy outcomes, offering a promising strategy to overcome limitations of conventional immune checkpoint inhibitors.
-
Annexin A2 Autoantibody in Pediatric Nephrotic Syndrome: Mec
2026-04-29
This study uncovers the pathogenic role of annexin A2 autoantibody in children with primary nephrotic syndrome, specifically minimal change disease and focal segmental glomerulosclerosis. Through multi-modal analysis, the research demonstrates how this autoantibody disrupts podocyte function via altered phosphorylation signaling, providing targets for mechanistic investigation and workflow optimization.
-
Neuroligin 1 Loss in Striatal D2-MSNs Drives Repetitive Beha
2026-04-29
This study demonstrates that deletion of Neuroligin 1 (NLGN1) in striatal D2 receptor-expressing medium spiny neurons (D2-MSNs) leads to hyperactivity of these cells and excessive repetitive behaviors in mice. By integrating molecular, behavioral, and single-nucleus RNA sequencing, the authors identify PKC overactivation as a mechanistic driver and suggest circuit-level targets for intervention in autism-related restricted, repetitive behaviors.
-
NSC 87877: Shp2 Inhibitor Workflows for Neuroinflammation Re
2026-04-28
NSC 87877, a highly selective Shp2 inhibitor from APExBIO, enables precise modulation of neuroinflammatory pathways and disease models. This guide details actionable protocols, troubleshooting strategies, and advanced applications, drawing directly from recent mechanistic breakthroughs and peer-reviewed insights.
-
Quizartinib (AC220): Applied FLT3 Inhibition for AML Researc
2026-04-28
Quizartinib (AC220) accelerates acute myeloid leukemia research with robust, highly selective FLT3 inhibition in both cell-based and in vivo models. This guide delivers actionable protocols, troubleshooting insights, and translational context to help you maximize the reliability and impact of your FLT3 signaling experiments.
-
Jiedu Xiaozheng Yin Promotes M1 Macrophage Polarization in C
2026-04-27
This study demonstrates that Jiedu Xiaozheng Yin (JXY), a traditional Chinese medicine, significantly suppresses the progression of colitis-associated colorectal cancer by promoting macrophage polarization toward the pro-inflammatory M1 phenotype via the TLR4 pathway. These findings provide mechanistic insights into macrophage modulation for tumor inhibition and highlight new avenues for immunomodulatory interventions in colorectal cancer.
-
MG-262 (Z-Leu-Leu-Leu-B(OH)2): Precision Proteasome Inhibiti
2026-04-27
MG-262 (Z-Leu-Leu-Leu-B(OH)2) empowers researchers with reversible, nanomolar-level proteasome inhibition, delivering robust modulation of apoptosis and cell cycle pathways in both in vitro and in vivo systems. Its high selectivity and cell permeability make it indispensable for sensitive proteasome activity assays, osteoclast differentiation studies, and advanced signaling research.
-
Triptolide (PG490): Transcriptional Disruption and Genome St
2026-04-26
Discover how Triptolide (PG490) uniquely modulates transcription machinery, impairs cancer cell invasion, and safeguards genome integrity. This article provides advanced mechanistic insight and protocol guidance, deepening understanding for researchers seeking precise cancer research solutions.
-
GluN2A/2B Regulation of Connexins in TMJ Inflammation-Induce
2026-04-25
This study reveals that N-methyl-D-aspartate receptor (NMDAR) subunits GluN2A and GluN2B distinctly mediate the expression of connexins and pannexins in the trigeminal ganglion during temporomandibular joint (TMJ) inflammation, contributing to orofacial inflammatory allodynia. The findings clarify peripheral sensitization mechanisms and highlight new molecular targets for pain management.
-
MLN4924: NEDD8-Activating Enzyme Inhibitor for Cancer Resear
2026-04-24
MLN4924 offers unparalleled selectivity and potency for dissecting the neddylation pathway in cancer biology research. This article details experimental workflows, troubleshooting strategies, and advanced applications—anchored by benchmarks and the latest literature—making MLN4924 essential for robust ubiquitination inhibition and tumor model studies.
-
PERK-Dependent JAK1–STAT3 Activation Drives Pyroptosis in Di
2026-04-24
This study delineates how endoplasmic reticulum stress (ERS) triggers pyroptotic cell death in nucleus pulposus cells via a PERK/eIF2α/ATF4-mediated activation of the JAK1–STAT3 pathway. These mechanistic insights clarify the molecular link between ERS and intervertebral disc degeneration, highlighting new therapeutic targets for mitigating disc cell loss and inflammation.
-
Suspension Culture Enables Serosal Mesothelium in Human Inte
2026-04-23
Capeling et al. introduce suspension culture as a simplified method to generate human intestinal organoids (HIOs) that develop an organized serosal mesothelial layer, closely resembling native human intestinal serosa. This advancement improves the in vitro modeling of intestine development and provides a platform for studying serosal biology and differentiation mechanisms.
-
Colorectal Cancer Organoids Drive Distinct Treg Differentiat
2026-04-23
This study establishes that colorectal cancer (CRC) organoids can directly induce a unique population of regulatory T (Treg) cells from CD4+ T cells through a TGFβ-dependent mechanism. The findings illuminate transcriptional and functional differences between tumor-induced and conventional Treg cells, providing new perspectives for tumor immunology and therapeutic targeting.
-
Cisplatin as a Precision Genotoxic Probe: Decoding DNA Repai
2026-04-22
Explore how Cisplatin (CDDP) advances cancer research by uniquely bridging DNA crosslinking, apoptosis, and the emerging role of RNA m6A regulation. This article delivers a deeper mechanistic perspective and practical protocols for next-generation apoptosis assays and chemoresistance studies.